Roche-backed biotech re­fu­els with $40M to steer neu­ro­mus­cu­lar can­di­date to­ward late-stage tri­als

Four years af­ter re­ceiv­ing back­ing from Roche to see if it can carve out a unique path in rare neu­ro­mus­cu­lar dis­or­ders, Aarhus, Den­mark-based NMD Phar­ma has re­loaded with al­most $40 mil­lion (€35 mil­lion) to con­tin­ue on it.

While NMD — whose name re­flects the strict fo­cus on that dis­ease area — was en­tire­ly a pre­clin­i­cal con­cept back then, the biotech has since man­aged to put a lead can­di­date in the clin­ic, said CEO Thomas Holm Ped­er­sen.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER